Gary A. Lyons Sells 40,000 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Gary A. Lyons sold 40,000 shares of the company’s stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $14.73, for a total value of $589,200.00. Following the completion of the transaction, the director now directly owns 51,000 shares of the company’s stock, valued at $751,230. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock opened at $15.26 on Tuesday. The firm has a market cap of $1.16 billion, a PE ratio of -7.27 and a beta of 0.73. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $15.58. The business’s fifty day simple moving average is $11.20 and its 200-day simple moving average is $8.73.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. The company had revenue of $54.12 million during the quarter, compared to analyst estimates of $49.50 million. Equities analysts forecast that Travere Therapeutics, Inc. will post -3.95 earnings per share for the current year.

Hedge Funds Weigh In On Travere Therapeutics

Hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. raised its position in Travere Therapeutics by 912.5% in the second quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock valued at $18,200,000 after purchasing an additional 1,995,419 shares during the period. Parkman Healthcare Partners LLC grew its stake in shares of Travere Therapeutics by 76.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock valued at $9,159,000 after buying an additional 441,318 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Travere Therapeutics by 79.2% in the 1st quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after buying an additional 81,611 shares during the period. GSA Capital Partners LLP acquired a new position in Travere Therapeutics during the 1st quarter worth about $452,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Travere Therapeutics during the 4th quarter valued at about $5,711,000.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Piper Sandler lifted their target price on shares of Travere Therapeutics from $11.00 to $12.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Canaccord Genuity Group decreased their price target on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Barclays upped their price objective on shares of Travere Therapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Tuesday, October 1st. Wedbush raised their target price on shares of Travere Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, Bank of America dropped their price target on Travere Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.09.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.